StemCyte International (TPE:4178) Change In Receivables: NT$-9.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
17 GF Score
Price NT$16.90
! 4 Warning Signs
View Full Analysis

What is StemCyte International Change In Receivables?

StemCyte International TPE:4178 +1.81% 17 Change In Receivables is NT$-9.9 Mil as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

StemCyte International's change in receivables for the quarter that ended in Mar. 2026 was NT$-1.0 Mil. It means StemCyte International's Accounts Receivable increased by NT$1.0 Mil from Dec. 2025 to Mar. 2026 .

StemCyte International's change in receivables for the fiscal year that ended in Dec. 2025 was NT$-0.3 Mil. It means StemCyte International's Accounts Receivable increased by NT$0.3 Mil from Dec. 2024 to Dec. 2025 .

StemCyte International's Accounts Receivable for the quarter that ended in Mar. 2026 was NT$91.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. StemCyte International's Days Sales Outstanding for the three months ended in Mar. 2026 was 95.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. StemCyte International's liquidation value for the three months ended in Mar. 2026 was NT$975.8 Mil.

StemCyte International  (TPE:4178) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

StemCyte International's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=91.595/87.809*91
=95.18

2. In Ben Graham's calculation of liquidation value, StemCyte International's accounts receivable are only considered to be worth 75% of book value:

StemCyte International's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2124.938-1418.913+0.75 * 91.595+0.5 * 402.178
=975.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Change In Receivables Related Terms

StemCyte International Change In Receivables Historical Data

* Premium members only.

The historical data trend for StemCyte International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Change In Receivables Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Receivables
7.24 -16.24 -25.14 -0.26

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.66 2.91 -13.05 1.23 -0.98
TPE:4178
17GF Score
StemCyte International Ltd TPE:4178
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCyte International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-9.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-9.9 Mil mean?
StemCyte International (TPE:4178) has a Change In Receivables of NT$-9.9 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for StemCyte International and its competitors.
Is StemCyte International's Change In Receivables too high?
StemCyte International's current Change In Receivables is NT$-9.9 Mil. Overall, StemCyte International has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Change In Receivables compare to VRTX and REGN?
StemCyte International's Change In Receivables of NT$-9.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for StemCyte International and its competitors. StemCyte International's current Change In Receivables is NT$-9.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Change In Receivables of NT$-9.9 Mil. The current Change In Receivables is NT$-9.9 Mil. StemCyte International's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Change In Receivables is NT$-9.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
17GF Score

Get the complete analysis for TPE:4178

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.90
Price